Research
Hormonal
Semaglutide reduced frailty burden after 52 weeks of treatment.
Semaglutide may be beneficial in reducing frailty in patients with obesity-related HFpEF over a year.
StrongSupportsmedium confidence
Semaglutide reduced the burden of frailty during follow-up (OR for being nonfrail at 52 weeks: 3.16 [95% CI: 2.44-4.09]; P < 0.0001).
Why this rating
Based on the large RCT design of the STEP-HFpEF program.
Source
Frailty and Effects of Semaglutide in Obesity-Related HFpEF
Ambarish Pandey et al. · JACC Heart Failure · 2025
DOI 10.1016/j.jchf.2025.102610
rctCited 4×
Read the paper DOI resolved against Crossref · corpus check 2026-06-10
More from this paper
Related findings · Hormonal
- Initial treatment for type 2 diabetes should be a combination of metformin and either an SGLT-2 inhibitor or a GLP-1 receptor agonist to achieve cardiorenal protection, rather than monotherapy or older agents like sulfonylureas.Strong
- For patients with specific monogenic obesity syndromes (leptin deficiency, POMC/PCSK1/LEPR mutations), targeted pharmacotherapy (recombinant leptin or setmelanotide) is highly effective and should be prioritized, unlike in polygenic obesity.Strong
- Continued weekly administration of 2.4 mg subcutaneous semaglutide prevents weight regain and promotes further weight loss in adults with overweight or obesity, whereas switching to placebo results in significant weight regain.Strong
This is one finding among thousands. Every one is graded and traced to its source, so you can see what the evidence actually supports. Browse the research →